2. Academic Validation
  3. Molecular mechanism of S100P promotes hepatocellular carcinoma by regulating MYBL2-mediated transcription of AURKB

Molecular mechanism of S100P promotes hepatocellular carcinoma by regulating MYBL2-mediated transcription of AURKB

  • Cell Signal. 2026 Jul:143:112490. doi: 10.1016/j.cellsig.2026.112490.
Lingyi Zhu 1,  Guang Li 1,  Chenjie Wang 1,  Lingming Bu 1,  Xiangwei Wu 2,  Xueling Chen 3
Affiliations

Affiliations

  • 1 School of Medicine, Shihezi University, Shihezi, China; Central Asian Laboratory for Prevention and Treatment of High - incidence Diseases, National Health Commission, Shihezi, China.
  • 2 School of Medicine, Shihezi University, Shihezi, China; Department of Hepatobiliary Surgery, the First Affiliated Hospital of Shihezi University, Shihezi, China. Electronic address: [email protected].
  • 3 School of Medicine, Shihezi University, Shihezi, China; Central Asian Laboratory for Prevention and Treatment of High - incidence Diseases, National Health Commission, Shihezi, China. Electronic address: [email protected].
PMID: 41856224 DOI: 10.1016/j.cellsig.2026.112490
Abstract

Hepatocellular carcinoma (HCC) progression involves the synergistic roles of S100P and AURKB. Using bioinformatics, molecular assays, and in vitro/vivo models, we show that S100P activates the RAGE/Ras/p-p38/NFκB pathway, upregulating MYBL2, which directly enhances AURKB transcription. Clinically, S100P correlates positively with AURKB expression and tumor immune suppression. HCC cells with low S100P expression showed significantly greater sensitivity to the AURKB inhibitor AZD1152-HQPA than control cells, with a 61% decrease in IC₅₀. This study reveals the S100P/MYBL2/AURKB axis as a key driver of HCC and a predictor of targeted therapy response, supporting precision treatment strategies.

Keywords

AURKB; Hepatocellular carcinoma; MYBL2; Precision therapy; S100P.

Figures
Products
Inhibitors & Agonists
Other Products